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Abstract
Background: The epithelial to mesenchymal transition (EMT) has been implicated in metastasis and therapy
resistance of carcinomas and can endow cancer cells with cancer stem cell (CSC) properties. The ability to
detect cancer cells that are undergoing or have completed EMT has typically relied on the expression of cell
surface antigens that correlate with an EMT/CSC phenotype. Alternatively these cells may be permanently
marked through Cre-mediated recombination or through immunostaining of fixed cells. The EMT process is dynamic,
and these existing methods cannot reveal such changes within live cells. The development of fluorescent sensors that
mirror the dynamic EMT state by following the expression of bona fide EMT regulators in live cells would provide a
valuable new tool for characterizing EMT. In addition, these sensors will allow direct observation of cellular plasticity
with respect to the epithelial/mesenchymal state to enable more effective studies of EMT in cancer and development.
Results: We generated a lentiviral-based, dual fluorescent reporter system, designated as the Z-cad dual
sensor, comprising destabilized green fluorescent protein containing the ZEB1 3′ UTR and red fluorescent
protein driven by the E-cadherin (CDH1) promoter. Using this sensor, we robustly detected EMT and mesenchymal
to epithelial transition (MET) in breast cancer cells by flow cytometry and fluorescence microscopy. Importantly, we
observed dynamic changes in cellular populations undergoing MET. Additionally, we used the Z-cad sensor
to identify and isolate minor subpopulations of cells displaying mesenchymal properties within a population
comprising predominately epithelial-like cells. The Z-cad dual sensor identified cells with CSC-like properties
more effectively than either the ZEB1 3′ UTR or E-cadherin sensor alone.
Conclusions: The Z-cad dual sensor effectively reports the activities of two factors critical in determining the
epithelial/mesenchymal state of carcinoma cells. The ability of this stably integrating dual sensor system to
detect dynamic fluctuations between these two states through live cell imaging offers a significant improvement over
existing methods and helps facilitate the study of EMT/MET plasticity in response to different stimuli and in cancer
pathogenesis. Finally, the versatile Z-cad sensor can be adapted to a variety of in vitro or in vivo systems to elucidate
whether EMT/MET contributes to normal and disease phenotypes.
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Background
Many cancers, including breast cancer, initially respond
to targeted therapy, chemotherapy, or radiotherapy, but
the development of resistance to these therapies and
subsequent tumor recurrence remain major clinical
problems. The majority of breast cancer-related deaths
are attributed to metastasis, and metastatic tumors are
also associated with therapy resistance [1]. Cells within a
particular tumor may display significant phenotypic vari-
ability, which can lead to differential responses to ther-
apy. The epithelial to mesenchymal transition (EMT)
can endow normal and breast cancer cells with stem
cell and cancer stem cell (CSC) properties, respect-
ively [2–4]. Evidence from neoadjuvant breast cancer
clinical trials suggests that after chemotherapy or tar-
geted therapy, the surviving tumor cells display a
CSC- and EMT-like gene expression profile, suggest-
ing that cancer cells with EMT-like properties can
resist these therapies [5]. Moreover, residual cells with
an EMT/CSC signature may progress to more aggres-
sive and therapeutically refractory tumors. Further
evidence has accumulated in breast and other carcinomas
that EMT enables cells to evade conventional treatments
[6–10]. These studies highlight the need for strategies to
target cells that have undergone an EMT in cancer. Alter-
natively, strategies that revert mesenchymal cells to a
more epithelial state may render them susceptible to
standard of care therapies [11].
EMT may also be required in some primary tumors
for the metastatic process of invasion and intravasation
in which only a small fraction of cells survive, as epithe-
lial cells usually undergo anoikis when they lose contact
with the basal lamina [12]. The few surviving cells must
then extravasate and colonize secondary organs to estab-
lish metastases, where the reverse process, mesenchymal
to epithelial transition (MET), may then be required for
metastatic cells to proliferate and grow into life-
threatening macrometastases [13, 14]. Provocatively,
these studies suggest that EMT/MET plasticity itself,
and not just a static epithelial or mesenchymal pheno-
type, plays a major role in pathogenicity. However, the
ability of cancer cells to exhibit cellular plasticity with
respect to EMT and MET has been difficult to study, as
methods that enable direct observations of phenotypic
plasticity in live cells are limited. The development of
stable sensors of CSC/EMT regulatory factors that mir-
ror dynamic changes in cellular states to isolate, analyze,
and observe living cells should allow us to monitor
EMT/MET plasticity in real time and improve our un-
derstanding of these processes.
To better identify mesenchymal-like cells or cells
undergoing EMT among a heterogeneous population,
cells that may be resistant to therapy and mediate
metastasis, we developed lentivirus-based fluorescent
sensors that stably integrate into a cell’s genome and re-
port changes in bona fide regulators of EMT. In this
study we generated a dual fluorescent sensor system,
designated as the Z-cad dual sensor system, which com-
prises two individual sensors: a constitutively expressed,
destabilized green fluorescent protein (GFP) reporter
regulated by the ZEB1 3′ untranslated region (UTR) and
a red fluorescent protein (RFP) reporter driven by the E-
cadherin (CDH1) promoter. ZEB1 is a potent inducer of
EMT and mediates its effects in part through direct sup-
pression of E-cadherin transcription [15]. ZEB1 forms a
double-negative feedback loop with the miR-200 family
of microRNAs, which induce MET by binding to the
ZEB1 3′ UTR, thus inhibiting ZEB1 translation [16–19].
E-cadherin is a common epithelial effector molecule that
mediates epithelial cell interactions, and inhibition of its
expression is associated with EMT [20]. Here we vali-
dated the function of these sensors by identifying MET
from mesenchymal-like breast cancer and conversely
EMT from epithelial-like cells. In addition we used these
sensors to successfully isolate cells with EMT and CSC
properties from a heterogeneous population. Import-
antly, we were able to identify changes over time in a
transitioning population using fluorescent microscopy,
demonstrating the ability to observe dynamic changes
from the mesenchymal to the epithelial state. Finally, we
show that a subset of cells that have permanently under-
gone EMT, as identified by their Z-cad sensor fluores-
cence pattern and morphology, can be forced to
undergo MET through epigenetic reprogramming using
a DNA methyltransferase inhibitor.
Results
Construction and validation of fluorescent EMT sensors
To establish inducible models that alter the EMT state
of carcinoma cells, we selected three mesenchymal-like,
claudin-low breast cancer models: the human MDA-
MB-231 cell line, the mouse T11 cell line [21], and the
human BLSL12 breast cancer cell line derived from the
WHIM12 patient-derived xenograft (PDX) [22]. To in-
duce MET in these cells, we transduced each cell line
with the pINDUCER lentivirus [23] containing the
doxycycline-inducible human miR-200c/141 cluster
(miR-200c), followed by selection for provirus-positive
cells. We confirmed that the mesenchymal-like claudin-
low cells switch to an epithelial-like (MET) morphology
upon miR-200c induction as compared to non-induced
cells (Fig. 1a). Induction of miR-200c (+DOX) was con-
firmed by qRT-PCR in each cell line (Fig. 1b). MET was
further confirmed by reduced ZEB1 expression and
increased E-cadherin expression in each cell line by
qRT-PCR and western blot analysis (Fig. 1b–c).
To generate stable fluorescent sensors that can identify
carcinoma cells with EMT or MET properties, we used
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the lentiviral expression vector FUGW, which expresses
eGFP from the constitutively active ubiquitin C (UbC)
promoter [24]. The human ZEB1 3′ UTR, a direct target
of miR-200 family members containing eight miR-200
target sequences [25], or a 3′ UTR containing five miR-
200 target sequences was inserted downstream of GFP
(Fig. 2a and Additional file 1: Figure S1A). It is import-
ant to note that the ZEB1 3′ UTR sensor does not report
transcriptional activity of the ZEB1 promoter, but in-
stead reports post-transcriptional regulation of ZEB1 via
its 3′ UTR. The eGFP fluorescent protein has a stability
of >24 hours [26], which prevents rapid detection of
decreasing GFP protein expression. Because we were in-
terested in detecting rapid changes in GFP in response
to changes in miR-200 family member activity (e.g.,
GFPhi to GFPlow/neg), we replaced eGFP with a destabi-
lized GFP (d2GFP), which has a half-life of about 2 hours
[27]. We designated the sensor using the human ZEB1
3′ UTR as d2GFP-Z1 3′ UTR and the 3′ UTR contain-
ing five miR-200 target sequences as d2GFP-200. Use of
these sensors in mesenchymal-like cells and cells under-
going an EMT, which express low levels of miR-200 fam-
ily members, should result in high GFP expression.
Conversely, their use in epithelial-like cells or cells
undergoing an MET, which have increased miR-200
expression, should result in low GFP expression by at-
tenuation of GFP translation (Fig. 2a). Therefore, these
GFP-based sensors should identify EMT (or mesenchymal
Fig. 1 miR-200c/141 expression elicits MET in claudin-low breast cancer. a MDA-MB-231, T11, and BLSL12 cells treated with 2 μg/mL doxycycline
(+DOX) for 4 days undergo morphological MET (n = 3 biological replicates). Scale bar = 20 μm. b qRT-PCR analysis of indicated genes after 4 days
of DOX treatment, n = 3. c Western blot analysis for indicated proteins after 4 days of DOX treatment
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cells) versus MET (or epithelial cells) states as a function
of changing miR-200 levels.
Although our GFP-based sensors report a single aspect
of EMT regulation (namely miR-200 expression and
other regulators of ZEB1 via its 3′ UTR), many other
factors can determine an epithelial versus mesenchymal-
like state. The use of multiple detectors of EMT should
provide greater resolution in identifying changes in cel-
lular state. The human E-cadherin (CDH1) promoter
contains three proximal E-boxes that serve as binding
sites for E-cadherin transcriptional repressors including
ZEB1, ZEB2, Snail, and Slug [28]. E-cadherin is not
expressed in the mesenchymal state, and its loss
promotes EMT and CSC properties [29]. Therefore,
to detect the presence of an addition regulator of an
epithelial versus mesenchymal state, we replaced the
cytomegalovirus (CMV) promoter in a pHAGE lenti-
viral vector that expresses dsRed [30] with the E-
cadherin promoter. We have designated this as the
Ecad-RFP sensor (Fig. 2a). Simultaneous introduction
of the GFP- and RFP-based sensors, therefore, should
allow robust identification of both epithelial- and
mesenchymal-like cells. Furthermore, this dual sensor
approach should provide an additional level of specifi-
city by helping to distinguish general effects on tran-
scription and microRNA biogenesis.
Fig. 2 The Z-cad dual sensor detects MET in claudin-low human and mouse breast cancers. a (Left) The d2GFP-Z1 3′ UTR sensor constitutively
expresses destabilized GFP (d2GFP) under control of constitutively active ubiquitin C promoter (UbC). The human ZEB1 3′ UTR containing eight
miR-200 binding sites was cloned downstream of d2GFP. (Right) The Ecad-RFP sensor contains about 1370 bp of the human E-cadherin promoter
regulating dsRED (RFP) expression. Three E-boxes proximal to transcription start site are indicated. Co-transduction of both sensors yields cells
containing the Z-cad dual sensor. b Flow cytometric analysis of human MDA-MB-231 breast cancer cells, mouse T11 breast cancer cells, and
human BLSL12 PDX-derived cells containing the Z-cad sensor. miR-200c/141 was induced with 2 μg/mL doxycycline for 4 days and flow
cytometry was performed. Epithelial (MET)- and mesenchymal (EMT)-enriched populations are as indicated (n = 3 biological replicates per group).
c Fluorescent confocal microscopy of MDA-MB-231 cells imaged at indicated time points during induction (+DOX) of miR-200c. –DOX is
non-induced control. Scale bar = 50 μm
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To test the function of these sensors, each claudin-low
cell line containing inducible miR-200c was co-transduced
with the d2GFP-Z1 3′ UTR and the Ecad-RFP sensors,
which, when used in combination, we have designated as
the Z-cad dual sensor. If the sensors function properly in
cells containing the Z-cad dual sensor, miR-200c should
directly suppress GFP (and endogenous ZEB1) expression
via the ZEB1 3′ UTR. Reduction of endogenous ZEB1, in
turn, should elicit de-repression of RFP regulated by the
E-cadherin promoter (Fig. 2a). We induced miR-200c ex-
pression and performed flow cytometry analysis for GFP
and RFP. The non-induced cells expressed GFP and little
to no RFP, the expected fluorescent characteristics of
EMT cells harboring the Z-cad dual sensor, in MDA-MB-
231, T11, and BLSL12 cells (Fig. 2b, –DOX). However, in
each cell line tested, miR-200c induction inhibited GFP
expression and induced RFP expression from the Z-cad
dual sensor, the expected fluorescent characteristics of
MET cells, validating the ability of these sensors to suc-
cessfully report MET (Fig. 2b, +DOX). We saw a similar
effect in each cell line with combinatorial use of d2GFP-
200/Ecad-RFP (Additional file 1: Figure S1C–D). Control
GFP expression was not reduced upon miR-200c induc-
tion as shown in Additional file 1: Figure S1C–D.
To demonstrate the ability of the Z-cad dual sensor to
detect dynamic changes in response to stimuli affecting
the mesenchymal state, we treated MDA-MB-231 cells
containing the Z-cad dual sensor with DOX to induce
miR-200c and imaged the cells over the course of
72 hours. We first observed loss of GFP expression be-
tween 4 and 6 hours (Additional file 2: Figure S2B), and
by 12 hours, almost all GFP expression was non-
detectable, whereas no changes in GFP fluorescence
levels were observed in the control (–DOX) cells (Fig. 2c
and Additional file 2: Figure S2A). RFP was first ob-
served to increase beginning at 32 hours (Additional file
2: Figure S2B) and continued to increase in intensity
throughout the 72 hours of DOX induction of miR-200c
(Fig. 2c and Additional file 2: Figure S2B). These results
demonstrated that in response to miR-200c expression,
GFP expression was rapidly lost and there was a delayed
but significant increase in RFP expression, as would be
expected because E-cadherin is an indirect downstream
target of miR-200c. The ability of the Z-cad sensor to
detect these dynamic changes is a significant improve-
ment over analysis of cells by immunostaining or via
flow cytometry at a single time point. Importantly, the
changes in GFP and RFP reflected the changes in ZEB1
and E-cadherin mRNA and protein levels (Fig. 1),
respectively, demonstrating that expression of these
fluorescent sensors reflected the expression of their en-
dogenous counterparts. We additionally confirmed the
changes in Z-cad fluorescence by microscopy in the
mouse T11 and human PDX-derived BLSL12 cells 4 days
after DOX treatment (Additional file 1: Figure S1B
and E). Therefore, using the Z-cad dual sensor sys-
tem, we were able to detect changes in the mesenchy-
mal state upon MET induction in both human and
mouse breast cancer cells.
The Z-cad dual sensor identifies EMT induced by TGFβ1 in
HMLER cells
Having validated the use of the Z-cad dual sensor system
to detect EMT/MET in claudin-low breast cancer cells
expressing inducible miR-200c, we next asked if we
could identify cells with EMT/MET properties using the
Z-cad dual sensor in response to TGFβ1. For this, we
used the epithelial-like, experimentally transformed hu-
man mammary epithelial cell line, HMLER [31]. HMLER
cells containing the Z-cad sensor were treated with
TGFβ1 (5 ng/mL) to induce EMT or vehicle over the
course of several days, as it took this time for the cells
to undergo an epithelial to mesenchymal switch. At the
end of the treatment, cells in the TGFβ1-treated group
had a high incidence of F-actin stress fibers, compared
with few stress fibers in the vehicle-treated cells, consist-
ent with cells exhibiting an EMT phenotype (Fig. 3a).
We harvested TGFβ1- versus vehicle-treated cells at sev-
eral time points throughout a 24-day treatment period
and performed qRT-PCR for EMT-associated genes.
Analysis of ZEB1, vimentin, E-cadherin, miR-200b, and
miR-200c expression levels demonstrated an early induc-
tion of the mesenchymal-associated genes ZEB1 and
vimentin (by 6 days) followed by a reduction of the
epithelial-associated genes E-cadherin and miR-200b
(Fig. 3b). We did not observe a significant reduction in
miR-200c RNA during the time course of the experi-
ment (Fig. 3b).
Next, we asked whether the observed changes in gene
expression were reflected by Z-cad dual sensor expression.
We noted that HMLER cells not treated with TGFβ1
displayed a wide range of RFP by flow cytometry analysis,
although the majority did express RFP (90 ± 3.0 % RFP-
positive cells; n = 8), suggesting that there is heterogeneity
in HMLER cells with respect to E-cadherin expression
(see Fig. 5). At day 14 of treatment, TGFβ1- or vehicle-
treated cells were assessed for differences in fluorescence
by microscopy. The majority of vehicle-treated cells
showed weak GFP expression and a wide range of RFP
levels (from weak to strong), whereas the TGFβ1-treated
cells displayed brighter GFP expression with fewer RFP-
expressing cells (Fig. 3c). In addition, the high GFP-
expressing cells in the TGFβ1-treated group frequently
appeared mesenchymal in morphology (Fig. 3c, arrows).
Flow cytometry analysis of the cells throughout the 24-day
treatment period showed a gradual increase in the propor-
tion GFPhi/RFPlow/neg (EMT signature) cells in the TGFβ1-
compared to vehicle-treated cells (Fig. 3d–e). The
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observed changes in gene expression (Fig. 3b) reflected
the increasing EMT population observed by flow cytome-
try, demonstrating that the Z-cad dual sensor was able to
identify cells that have undergone EMT in response to
TGFβ1.
The Z-cad dual sensor identifies differential plasticity in
EMT subpopulations of HMLER cells upon TGFβ1
exposure
To assess the plasticity of cells following TGFβ1 treat-
ment, we used fluorescent activated cell sorting (FACS)
to separate TGFβ1-treated cells into two populations,
the EMT signature cells and the bulk population de-
pleted of the EMT signature cells (Bulk-EMT) at 12 (data
not shown) or 24 days of treatment, and then, each
population was cultured for 13 days in the absence of
TGFβ1. Intriguingly, following 13 days of TGFβ1 re-
moval, the EMT signature cells were mesenchymal in
appearance and maintained their EMT fluorescence
signature (GFPhi/RFPlow/neg), whereas the Bulk-EMT cells
appeared only partially mesenchymal and displayed a
heterogeneous fluorescence signature (Fig. 4a). These
data suggest that only a subset of the parental HMLER
cells undergo complete EMT during TGFβ1 treatment,
whereas the majority of cells, even at late time points,
are still transitioning and display a partial mesenchymal
phenotype. The EMT signature sorted cells treated with
TGFβ1 displayed no capacity to revert to their parental
phenotype, both morphologically and by Z-cad expres-
sion, upon subsequent passaging after 13 days (data not
Fig. 3 The Z-cad sensor identifies EMT induced by TGFβ1 in HMLER cells. a F-actin stress fibers increase during TGFβ1 compared to vehicle treatment
(26 days) indicating EMT. Scale bar = 100 μm. b RNA analysis by qRT-PCR at indicated time points during vehicle or TGFβ1 treatment (n = 3 biological
replicates per time point). Vehicle-treated values were set to 1.0 for each gene and analyzed using an unpaired Student’s t test. c Fluorescent confocal
microscopy indicating a gain of GFP and loss of RFP at 14 days of TGFβ1 versus vehicle treatment. Mesenchymal-appearing bright GFP
cells are indicated by arrows. Scale bar = 20 μm. d Flow cytometric analysis of HMLER cells containing Z-cad sensor showing an increase
in cells displaying GFPhiRFPlow/neg EMT fluorescence signature during TGFβ1 treatment at the times indicated. e Quantitation of cells
displaying the EMT signature in HMLER cells containing Z-cad dual sensor from d. Bar graphs depict the percentage of cells displaying
the EMT fluorescence signature in TGFβ1- versus vehicle-treated groups (n = 3 biological replicates per time point). Data were analyzed
using an unpaired Student’s t test. * p value < 0.05, ** p value < 0.01
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shown). However, FACS-isolated parental HMLER cells
that displayed the EMT signature and were never ex-
posed to TGFβ1 eventually re-expressed RFP, lost GFP
expression, and lacked the full mesenchymal morph-
ology (Fig. 4b). This suggested that parental HMLER
cells that display the EMT signature retain plasticity, as
they have the capacity to undergo MET. Together, these
data indicate that TGFβ1 treatment reprograms a subset
of HMLER cells and inhibits their capacity for EMT/
MET plasticity.
HMLE cells, from which the HMLER cells are derived,
undergo spontaneous EMT with concomitant methyla-
tion of miR-200c, re-expression of which induces MET
[32]. Therefore, we hypothesized that prolonged expos-
ure of cancer cells to TGFβ1 potentially induces DNA
methylation and fixes cells in the mesenchymal state. To
test this hypothesis, we treated fully transitioned
HMLER EMT cells with the DNA methyltransferase
inhibitor decitabine for 5 days. Decitabine treatment re-
duced the number of cells displaying the Z-cad EMT sig-
nature compared to vehicle-treated cells (Fig. 4c).
Quantitation of RFP expression showed a significant in-
crease in RFP+ cells from 1.09 % in vehicle-treated cells
to 2.84 % (p = 0.006) and 5.33 % (p = 0.003) for 100 nM
and 500 nM decitabine-treated cells, respectively (Add-
itional file 3: Figure S3). Moreover, we observed a signifi-
cant increase in GFPlow expressing cells in vehicle-
treated cells from 4.63 % to 8.07 % (p = 0.007) and
15.7 % (p = 0.0000002) for 100 nM and 500 nM decita-
bine treated cells, respectively (Additional file 3: Figure
S3). Decitabine-treated cells acquired the expression of
E-cadherin, miR-200b, and miR-200c, and reduced ZEB1
expression (Fig. 4d). Thus, the changes in the Z-cad sen-
sor reflect the changes in the endogenous expression of
these genes. These data further suggest that the perman-
ent EMT induced by TGFβ1 treatment may be due, at
Fig. 4 The Z-cad sensor identifies differential plasticity in HMLER EMT subpopulations upon TGFβ1 exposure. a HMLER cells cultured for 24 days
with TGFβ1 were sorted into EMT and Bulk–EMT groups and allowed to grow in the absence of TGFβ1 for 13 days. b Parental HMLER cells were
grown sorted into EMT and Bulk–EMT groups and allowed to grow for 13 days. c HMLER EMT cells were grown in the presence of the indicated
concentrations of decitabine (or vehicle) for 5 days. Medium was changed daily with fresh decitabine. Flow cytometry was performed and the
EMT fluorescence signature is indicated (n = 3 biological replicates for vehicle and 500 nM; n = 2 biological replicates for 100 nM). d qPCR analysis
for the indicated genes at different decitabine concentrations is shown. Vehicle treated values were set to 1.0 for each gene. Each concentration
was compared to vehicle and analyzed using an unpaired Student’s t test (n = 3 biological replicates per group). * p value < 0.05, ** p value < 0.01.
All scale bars = 20 μm
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least in part, to epigenetic silencing of epithelial genes
by DNA methylation, and this can be reversed, in at
least a subset of cells, by DNA methyltransferase
inhibition.
Combinatorial use of EMT sensors detects rare
mesenchymal-like cells among a heterogeneous
population largely comprising epithelial-like cells
It is apparent that considerable heterogeneity exists in
most established epithelial cell lines. Parental HMLER
cells cluster into the basal-like breast cancer subtype and
contain a small population of CD24low/neg/CD44hi CSCs
that also display EMT properties [2, 33]. In our studies
using HMLER cells, TGFβ1 treatment slowly induced
EMT, and the transition only appeared to be complete
in a subset of cells. Notably, the Z-cad dual sensor
allowed the resolution of cells displaying a partial versus
complete EMT during TGFβ1 treatment, suggesting that
there is significant heterogeneity within the HMLER
population during TGFβ1-induced EMT. Therefore, we
next asked whether parental HMLER cells display
epithelial/mesenchymal heterogeneity similar to that
observed during TGFβ1 induction of EMT, and if the Z-
cad dual sensor can resolve distinct cellular populations
prior to experimental induction of EMT. Using fluores-
cent microscopy, we observed differences in the intensity
of fluorescence among individual cells, and we identified
a small subpopulation of GFP+RFPneg cells that appeared
mesenchymal in morphology (Fig. 5a). Flow cytometry
analysis (Fig. 5b) of parental HMLER cells also showed a
group of GFPhiRFPlow/neg cells, similar to the EMT signa-
ture cells that expanded during TGFβ1 treatment (Fig. 3).
We asked whether cells falling within this EMT signa-
ture group in parental HMLER cells display character-
istics of mesenchymal cells even without experimental
EMT induction. Using FACS we separated cells dis-
playing the EMT signature (GFPhiRFPlow/neg) from the
Bulk-EMT cells. We cytospun the cells immediately
post sorting and performed co-immunofluorescence
for pan-cytokeratin (CK), an epithelial marker, and
vimentin, a mesenchymal marker. Although all cells
expressed basal levels of both CK and vimentin, the
immunofluorescent staining of vimentin was more in-
tense in the EMT signature associated cells relative to
the Bulk–EMT population (Fig. 5c). Moreover, RNA
analysis showed reduced expression of E-cadherin,
miR-200b, and miR-200c and increased expression of
ZEB1 in the EMT signature population relative to the
Bulk–EMT population (Fig. 5d). We also used the Z-
cad dual sensor system in MCF10A cells, which have
been shown to also be heterogeneous and contain a
more mesenchymal subpopulation [34], and observed a
similar RNA expression pattern when sorted into EMT
and Bulk–EMT populations to that observed in the
HMLER cells (Additional file 4: Figure S4). Finally,
sorted HMLER cells were cultured and their morph-
ology was assessed 48 hours post sorting. Bulk–EMT cells
appeared cobblestone-like and formed tightly organized
colonies, similar to the unsorted, parental HMLER cells
(Fig. 5e). Conversely, the EMT signature cells displayed
a loosely packed organization and were more mesenchy-
mal in morphology than the parental cells (Fig. 5e), but
similar to the sorted parental EMT signature cell
morphology observed 13 days after sorting (Fig. 4b).
Taken together, these data indicate that the Z-cad dual
sensor can be used to identify and isolate cellular sub-
populations that display mesenchymal-like morphology
and gene expression from a heterogeneous population
of cells.
During TGFβ1 treatment of HMLER cells (Fig. 3), we
observed a gradual induction of a complete EMT via for-
mation of a GFPhiRFPlow/neg population, and these cells
were more mesenchymal in morphology than the Bulk-EMT
population (Fig. 4a). While the entire TGFβ1-treated cell
population gained expression of mesenchymal genes early
on compared to the vehicle-treated cells, a decrease
in epithelial gene expression was delayed (Fig. 3b).
However, the separation of cells with the EMT signa-
ture from the Bulk–EMT population resolved differ-
ences in RNA and protein expression with respect to
EMT regulating factors during TGFβ1 treatment
(Additional file 5: Figure S5). This validated the abil-
ity of the Z-cad dual sensor to identify changes in
gene expression among a heterogeneous population
even when these changes were not apparent among
the entire TGFβ1-treated population as compared to
the vehicle-treated population until later time points.
Taken together, these data demonstrate that the Z-cad
dual sensor can be used to isolate and identify differ-
ent cellular populations within a heterogeneous popu-
lation displaying more mesenchymal gene expression
patterns and properties.
Z-cad dual fluorescence better identifies CSC-like cells
compared with either sensor alone
Previous studies have demonstrated that HMLE cells
contain a subpopulation of CSCs as demonstrated by
their CD24low/negCD44hi expression and mammosphere-
forming capacity [2, 32]. Because EMT has been linked
to CSC properties, we asked how well the HMLER cells
displaying an EMT signature, which were isolated using
the Z-cad dual sensor system from the parental HMLER
cells, correlated with HMLER cells displaying a CSC sig-
nature (CD24low/neg/CD44hi). Moreover, we wanted to
test whether the Z-cad sensor system could better iden-
tify CSCs than either sensor alone. We used flow cytom-
etry to distinguish cells displaying the GFPhiRFPlow/neg
EMT signature to those displaying GFPhi, RFPlow/neg,
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Bulk-EMT, and the total cellular population (Bulk), and
then quantified the percentage of these populations that
fell within the CSC-enriched CD24low/CD44hi popula-
tion (Fig. 6a–b; Additional file 6: Figure S6A–B). The
GFPhi only and the RFPlow only populations contained
more cells in the CD24low/neg/CD44hi, CSC-enriched
group than the Bulk population (13 % versus 2.5 %,
p = 0.0000037) and (6.1 % versus 2.5 %, p = 0.00052),
respectively, demonstrating that either sensor alone
can enrich for CSCs. Importantly, the EMT signature
population was the most highly enriched in the
CD24low/CD44hi CSC signature group compared with the
Bulk population (32 % versus 2.5 %, p = 0.00018) (Fig. 6b;
Additional file 6: Figure S6B), and compared with any of
the other populations, including GFPhi (p = 0.00074),
RFPlow (p = 0.00017), and Bulk–EMT (p = 0.00017) (Fig. 6b
and Additional file 6: Figure S6B). These data suggest that
the Z-cad sensor better enriches for CSCs than either sen-
sor alone.
To test the stem cell function of the EMT signature
cells isolated using the Z-cad sensor, we performed
tumorsphere assays. Importantly, the EMT signature
Fig. 5 The Z-cad sensor identifies and enables isolation of mesenchymal cells present among a heterogeneous population. a Fluorescent confocal
microscopy was performed on parental HMLER cells containing the Z-cad dual sensor. Scale bar = 20 μm. b FACS was performed on parental
HMLER cells to isolate mesenchymal-like GFPhiRFPlow/neg cells, which comprise the EMT signature. All other cells are designated as Bulk–EMT. c Cells
from each group in b were collected, cytospun, and stained for pan-CK and vimentin. d RNA from each group collected in b was isolated and
qRT-PCR performed for the indicated genes. Bulk–EMT cell values were set to 1.0 for each gene. Data were analyzed using a paired Student’s t test
(n = 7 biological replicates). e Cells isolated from each group in b were plated and grown for 48 hours. Scale bar = 20 μm
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cells formed tumorspheres (>75 μm) at a frequency of
about 3 %, much higher than the approximately 0.5 %
tumorsphere-forming capacity of the Bulk-EMT popula-
tion (Fig. 6c–d). In addition, cells falling into the
CD24low/neg/CD44hi CSC-enriched population formed
tumorspheres at a higher rate than the non-CSC (NCSC)
population (Fig. 6d). Confirming the ability of the Z-cad
sensor to identify cells with CSC properties, cells with
the EMT signature formed spheres at a similar efficiency
as that of the CSC-enriched population (Fig. 6d). These
data, therefore, demonstrated that the Z-cad dual sensor
facilitated the isolation of cells with EMT properties
from a mixed population, and furthermore, it was able
to enrich for cells with CSC properties to a greater ex-
tent than either sensor alone. Therefore, the Z-cad dual
sensor should provide a stable and facile method, in the
absence of immunostaining, for identifying and isolating
EMT/CSC-like cells by flow cytometry in this model as
well as for their detection via microscopy.
Discussion
In this study we have described the development and
validation of novel fluorescent reporter-based sensors
for the identification of an EMT/MET state. We also
demonstrated that the Z-cad dual sensor successfully re-
ports the regulation of two critical regulators of EMT.
One component of our Z-cad dual sensor system, the
ZEB1 3′ UTR sensor (and miR-200 sensor), reports the
activity of the miR-200 family of microRNAs. ZEB1 and
the miR-200 family represent a critical axis that deter-
mines epithelial/mesenchymal identity and may be re-
sponsible for EMT/MET plasticity [35, 36]. The ZEB1/
miR-200 axis likely has additional, non-cell autonomous
roles in cancer pathogenesis, as it has recently been
shown to affect immune recognition of cancer cells
whereby ZEB1 suppression of the miR-200 family leads
to upregulation of PD-L1, a direct miR-200 family target.
This leads to subsequent evasion of immune cells by the
tumor cells [37]. The study by Chen et al. [37] suggests
an ever-expanding role of EMT in regulating different
aspects of cancer and highlights the need to more fully
understand the critical ZEB1/miR-200 axis. The second
component of our Z-cad dual sensor system is a
promoter-based sensor that reports transcriptional regu-
lation of E-cadherin, the expression of which is lost dur-
ing EMT. This loss is mediated through direct
Fig. 6 The Z-cad dual sensor enriches for CSCs better than either sensor alone. a Analysis strategy for identifying CD24/CD44 expression of
HMLER cells first gated based on distinct Z-cad expression patterns. The CD24/CD44 plot shown here indicates the entire cellular population
(Bulk) without prior Z-cad gating. CD24 and CD44 negative box is shown in gray and was identified using singly stained samples. CSC-enriched
population (CD24low/neg/CD44hi) is shown in the red box. b Percentage of cells falling into CSC-enriched population (CD24lo/negCD44hi) first gated
on indicated Z-cad sensor fluorescence patterns. Bulk represents all cells. Data were analyzed using the paired Student’s t test (n = 6 biological
replicates). c HMLER cells were sorted into EMT and Bulk–EMT groups (shown) or CSC and NCSC (not shown) and were plated and grown under
tumorsphere conditions (1000 cells per well in a 96-well plate, 5 technical replicates per biological replicate, 3 biological replicates). d After
12 days, spheres >75 μm were quantified. Data were analyzed using the paired Student’s t test
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transcriptional suppression by ZEB1 and other inducers of
EMT, including ZEB2, Snail, and Slug, that target E-boxes
present in the E-cadherin promoter [20]. One potential
caveat is that the E-cadherin reporter component of this
sensor may not detect EMT in cases where E-cadherin is
post-transcriptionally regulated or its localization at the
cell membrane is lost, which can also induce EMT proper-
ties [38]. However, the GFP component of the Z-cad sen-
sor in these cases would still report the ZEB1/miR-200
axis. Additionally, it is not inconceivable that the Z-cad
sensor will have limited applicability in detecting EMT
regulated independently of miR-200, ZEB1, or E-cadherin.
Indeed, miR-200 and ZEB1 expression are highly inter-
twined, and ZEB1 does regulate E-cadherin expression.
However, a number of other transcription factors includ-
ing ZEB2, Slug, and Snail can also suppress E-cadherin ex-
pression; therefore, E-cadherin expression is not solely
dependent upon ZEB1. Nevertheless, the prevalence of
the ZEB1/miR-200 axis and E-cadherin in regulating EMT
suggests that the Z-cad sensor provides a widely applic-
able tool for studying the role of EMTand MET in cancer.
Our data demonstrate that the Z-cad sensor system
can be employed to determine whether EMT or MET
has occurred within heterogeneous populations of both
human and mouse cells and should facilitate the identifi-
cation and isolation of individual cells displaying EMT/
MET within a heterogeneous population. While not in-
vestigated directly in this study, the Z-cad sensor should
allow the detection of cells displaying a partial EMT
(e.g., GFPhiRFPhi), a state that is proposed to enhance
the invasive and CSC properties of cancer [39]. The po-
tential for the Z-cad sensor to detect different degrees of
EMT should aid in the study of a partial EMT phenotype
and its role in cancer pathogenesis. The lentiviral back-
bone of these sensors facilitates the introduction of sta-
bly integrated reporters into diverse tumor models
including transplantable models for in vivo studies. This
represents a benefit over conventional transgenic lineage
tracing models, and has potential utility in developmen-
tal studies, including embryonic mammary gland devel-
opment, a stage when EMT has been hypothesized to
occur [40].
A common method for detecting EMT/MET is by
using flow cytometry to correlate the EMT phenotype
with expression of cell surface antigens associated with
CSCs, including high CD44 expression in conjunction
with low CD24 or EPCAM expression. Although CD44
may regulate an EMT/CSC state, its specific function in
this process and whether its expression is a cause of or a
consequence of EMT/CSCs remain controversial [41].
Most likely certain alternatively spliced isoforms of
CD44 regulate the EMT/CSC properties of a cell, but
often the CD44 antibodies most commonly used in flow
cytometry studies to detect EMT/CSCs are not isoform
specific [42]. Importantly, the Z-cad sensor used in this
study reports expression of two critical regulators of
EMT with well-defined roles in the process. The en-
dogenous nature of the Z-cad sensor, once introduced
into cells, obviates the need for immunostaining, leading
to reductions in cost and time when performing these
analyses. Here we confirmed that the Z-cad dual sensor
enriched for cells with a CSC-enriched surface antigen
profile better than either component of the Z-cad sensor
alone. However, while the correlation between EMT and
CSC surface antigens has proven useful and relatively
accurate here and in other studies, CSCs do not neces-
sarily exhibit EMT properties, and EMT may not always
induce CSC properties [43, 44]. Thus, the Z-cad sensor
should provide an accurate indicator of EMT as regu-
lated by the ZEB1/miR-200 axis and E-cadherin tran-
scription, and its use will complement surface antigen
analysis in cases where CSC frequency and the EMT
phenotype do not correlate.
Lineage tracing of cells that have undergone an EMT
or MET has relied upon Cre-mediated recombination in
cells that express EMT-associated genes [9, 45, 46]. A
recent study by Zhao et al. demonstrated the ability to
observe EMT in vivo by live imaging using an FSP1-Cre
transgenic mouse breast cancer model in which the
authors were able to observe EMT within individual
cells [46]. However, Cre-based models lack the ability to
observe true plasticity between the EMT/MET states
during live imaging, as Cre-recombination is permanent
and only indicates whether a single transition occurred.
A recent study used an inducible Twist1 model to show
that a transient EMT must occur for CSC formation,
followed by a subsequent MET that promoted CSC
characteristics [47], emphasizing the relevance of moni-
toring transient changes in EMT/MET states. Import-
antly, we have demonstrated that the Z-cad sensor
allowed for the analysis of dynamic fluctuations between
an EMT and MET state in cell culture models, and this
technique should be adaptable to in vivo imaging
models, highlighting a significant improvement in the
ability to observe EMT/MET plasticity in real time.
While both established breast cancer cell lines and pri-
mary tumors exhibit cellular heterogeneity with respect
to EMT/CSC properties, and it has been shown that
EMT/CSC characteristics are enriched following treat-
ment with breast cancer therapies [5, 48], it is not
known whether these therapies induce an EMT or sim-
ply select for cells already displaying EMT properties.
Conversion from a non-CSC to CSC-like identity has
been demonstrated and is accompanied by changes in
EMT markers [33, 49]. This conversion may serve as a
mechanism for non-CSCs that are normally susceptible
to therapy to become more resistant, mesenchymal-like
cells. EMT is accompanied by a significant reduction in
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proliferation [13, 50], suggesting that the transition itself
may endow a cell with resistance to therapies that target
proliferating cells. However, this is most likely not the
only mechanism of resistance, as mesenchymal-like
claudin-low breast cancers, which are proliferative, also
display characteristics associated with therapy resistance,
suggesting that alternative resistance mechanisms exist
[5, 51]. Perhaps EMT/CSCs are better able to repair
their DNA in response to damage, as has recently been
shown for CSCs in a p53 null breast cancer model
[52]. Ultimately, the Z-cad sensor may be useful to
better address the question of whether plasticity itself
provides a resistance mechanism or, alternatively, if
preselection of resistant EMT-like cells results in
therapy resistance.
Experimental evidence has pointed to EMT/MET plas-
ticity as a requirement for different steps in the meta-
static cascade [13, 14], but these studies typically have
relied upon overexpression of EMT regulatory factors
and therefore, may not reflect what happens in cells that
activate or suppress endogenous EMT regulatory factors.
Two recent studies suggested that EMT does not in-
crease metastatic potential, highlighting the controversy
surrounding the role of EMT in metastasis. However,
both studies also reported that EMT still endowed cells
with therapy resistance in primary and metastatic tu-
mors [9, 10]. Although the data presented indirectly sug-
gested that EMT/MET plasticity occurs in the resistant
metastatic breast tumors, whether the resistant cells ac-
tually exhibited plasticity needs to be confirmed. Defin-
ition of the precise role of EMT in metastasis, therefore,
requires further study. Nevertheless, EMT appears to be
important in the pathogenesis of cancer. Here, we
provide evidence that the Z-cad sensor can be used to
isolate cells in a heterogeneous population without ex-
perimentally inducing/inhibiting an EMT, demonstrating
its ability to report endogenous expression of EMT regu-
lating factors. Moreover, the Z-cad dual sensor offers a
promising new tool for observing fluctuations in the
EMT/MET status of tumor cells, in real time, during dif-
ferent steps in the metastatic cascade.
Conclusions
The Z-cad dual sensor provides a novel method to de-
tect different EMT/MET states by reporting changes in
two critical regulators of EMT with well-defined roles in
this process. The ability of these sensors to report
changes both via flow cytometry and dynamic changes
in live cells using fluorescence microscopy in response
to different stimuli or even in an unperturbed setting
has several advantages over current methods that rely
on immunostaining or lineage tracing. The lentiviral na-
ture of the Z-cad dual sensor enables facile and stabile
introduction using both in vitro and in vivo models and
should aid in elucidating the mechanisms underlying
EMT/MET processes in the pathology of cancer.
Methods
Generation of lentiviral constructs
To construct the miR-200 sensor, four oligonucleotide
primers were generated containing five target sequences
recognized by each of the five miR-200 family member
seed sequences and annealed in vitro. The primers were
designed so that the annealed fragment had overhangs
that complement with the FUGW lentiviral vector
digested with BsrGI and EcoRI. The primers were also
designed to ensure that the eGFP cDNA in the FUGW
vector remained intact after ligation. The sequences of



















The miR-200 binding sites were subcloned into the
TOP-d2GFP vector. The d2GFP-miR200 sequence was
then amplified with a 5′ BamHI and 3′ NheI added and
inserted back into FUGW to replace eGFP. The TOP-
d2GFP vector was a kind gift from Drs. Wen Bu and Yi
Li (Baylor College of Medicine, Houston, TX). d2GFP
was subcloned into FUGW to replace eGFP and serve as
a d2GFP control vector. Briefly, primers to amplify in-
serts were generated to contain 5′ BamHI and 3′ NheI
restriction sites and inserted into FUGW and FUGW-
miR-200.
The ZEB1 3′ UTR (pRL-ZEB1) was a kind gift from
Dr. Joel Neilson (Baylor College of Medicine, Houston),
with permission of Dr. Gregory Goodall (University of
Adelaide, Australia). The ZEB1 3′ UTR was amplified
using primers to add NheI and EcoRI sites. The
d2FUGW-miR-200 vector was cut with NheI and EcoRI
and the ZEB1 3′ UTR was inserted.
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The human E-cadherin promoter (about 1370 bp)
replaced the CMV promoter into a modified pHAGE-
CMV-dsRed-IRES-ZsGreen vector in which IRES-
ZsGreen was previously removed.
To generate pINDUCER13-pre-miR-200c/141 (p13-
miR-200c/141), miR-200c/141 from p11-miR-200c-/141
[11] and p13 were both digested using NotI and MluI.
The miR-200c/141 sequence was inserted directly into
p13, which was a kind gift from Dr. Thomas Westbrook
(Baylor College of Medicine, Houston, TX).
All inserts were sequenced and verified after they were
cloned into destination vectors.
Cell culture and lentivirus transduction
The MDA-MB-231 cells were acquired from the Tissue
and Cell Culture Core Laboratory at Baylor College of
Medicine in Houston, TX, which originally obtained
them from the American Type Culture Collection
(ATCC), Manassas, VA. They were maintained in
DMEM (Gibco) supplemented with 10 % fetal bovine
serum (FBS) and antibiotic/antimycotic.
The T11 cells were derived from a p53 null, claudin-
low mouse mammary tumor [21]. They were cultured in
DMEM (Gibco) supplemented with 10 % FBS and anti-
biotic/antimycotic.
The BLSL12 cells were a kind gift from Dr. Matthew
Ellis (Baylor College of Medicine, Houston, TX). These
cells were derived from the WHIM12 claudin-low hu-
man patient derived xenograft [22]. They were cultured
in RPMI-1640 supplemented with high glucose, L-glu-
tamine, HEPES (ATCC 30-2001), 10 % FBS, and anti-
biotic/antimycotic.
The MCF10A cells were obtained from Dr. Dean
Edwards through the Advanced Technology Core at
Baylor College of Medicine in Houston, TX, which
originally obtained them from ATCC. They were main-
tained in DMEM/F12 (Gibco) supplemented with 5 %
horse serum, 20 ng/mL epidermal growth factor (EGF),
0.5 μg/mL hydrocortisone, 5 μg/mL insulin, 100 ng/mL
cholera toxin, and antibiotic/antimycotic.
The HMLER cells were obtained from Dr. Sendurai
Mani (MD Anderson Cancer Center, Houston, TX).
They were kept under puromycin selection to maintain
H-Ras (G12V) expression and were maintained in 50 %
MEGM medium (Lonza CC-3051) and 50 % DMEM/
F12 (Gibco) supplemented with 5 μg/mL insulin, 10 ng/
mL EGF, 500 ng/mL hydrocortisone, and antibiotic/anti-
mycotic. For EMT induction HMLER cells were treated
with 5 ng/mL recombinant human TGFβ1 (R&D Sys-
tems, 240-B). TGFβ1 was prepared according to the
manufacturer’s protocol.
All cell lines were transduced with lentiviral fluores-
cent sensors at a MOI = 5. HMLER and MCF10A cells
were sorted for double positive cells to ensure provirus
presence in all cells. MDA-MB-231, T11, and BLSL12
cells were transduced with p13-miR-200/141 (see below)
and selected for 3 days in 2 μg/mL puromycin. To in-
duce miR-200c/141, cells were treated with 2 μg/mL
doxycycline for the indicated time periods.
Decitabine (5-aza-2’-deoxycytidine) was purchased
from Sigma Aldrich (#A3656) and reconstituted in
DMSO. The medium was changed daily during treat-
ment studies.
Tumorsphere assays
The HMLER tumorsphere medium was made using
MEGM medium (Lonza CC-3051) without BPE with the
following supplements: 20 ng/mL bFGF, 10 ng/mL EGF,
4 ug/mL heparin, and 1 % methyl cellulose (to prevent
aggregation).
The cells were sorted according to the fluorescent sen-
sor or CD24/CD44 expression as indicated in the text.
Once sorted, the cells were centrifuged, washed two
times in mammosphere medium without BPE, and
counted. 1000 cells per well were plated in 100 μL mam-
mosphere medium (5 wells per group, per replicate) in a
low-attachment 96-well plate. Tumorsphere medium
(100 μL) was added every 3 days. Twelve days after seed-
ing, tumorspheres (>75 μm) were quantified. Five tech-
nical replicate experiments were performed for each of
the three biological replicates per group.
Western blot
Tumor cells were harvested by mechanical scraping and
resuspended in RIPA buffer containing protease and phos-
phatase inhibitors (Roche), placed on ice for 30 min, and
resuspended periodically. The lysed cells were centrifuged
and supernatants were isolated. The protein concentra-
tions were determined using a Bradford assay, loaded and
run on a 10 % Tris-glycine SDS-polyacrylamide gel. The
transfers were performed overnight at 4 °C. The following
antibodies and conditions were used: mouse monoclonal
Anti-β-Actin (Sigma-Aldrich, Clone AC-15, A5441)
1:5000 in 5 % milk in TBS-T, rabbit monoclonal Anti-E-
cadherin (Cell Signaling Technology, Clone 24E10, 3195S)
1:1000 in 5 % BSA in TBS-T, rabbit polyclonal Anti-ZEB1
(Santa Cruz Biotechnology, SC-25388) 1:500 in 5 % milk
in TBS-T.
RNA isolation and qRT-PCR
RNA isolation was performed using the miRNeasy Mini
Kit (Qiagen) and treated with the RNase-Free DNase
(Qiagen).
Reverse transcription of mRNAs was performed using
a High-Capacity RNA-to-cDNA Kit (Thermo Fisher Sci-
entific). 100 ng total RNA was used for each reaction.
cDNA was diluted to 1 ng/μL prior to qPCR. 2 ng of
cDNA was added to each well (each sample was
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performed in triplicate as technical replicates). The fol-
lowing TaqMan probes and primers from Thermo Fisher
were used for qRT-PCR: 18 s (Hs99999901_s1), human
Zeb1 (Hs00232783_m1), mouse Zeb1 (Mm0049556
4_m1), human CDH1 (Hs01013959_m1, mouse Cdh1
(Mm01247357_m1), and human vimentin (Hs00185
584_m1).
Reverse transcription (RT) PCR for miRNAs was per-
formed using the TaqMan Small RNA Assays (Thermo
Fisher) with corresponding miRNA assays as listed
below. 10 ng of total RNA was added to each reaction
and RT was performed according to the manufacturer’s
protocol. The following TaqMan RT primers and qPCR
probes and primers from Thermo Fisher were used for
qRT-PCR: U6 snRNA (001973), miR-200b (002251), and
miR-200c (002300).
TaqMan Gene Expression Master Mix (Thermo
Fisher) was used for all qPCR reactions. qPCR was per-
formed on a Step One Plus Real-Time PCR machine.
For non-detectable expression during qPCR, Ct values
were set to 39.
Microscopy
All fluorescent images were taken using a Nikon A1-R
confocal microscope with NIS Elements acquisition soft-
ware and analyzed using FIJI Software. IBIDI μ-Dish
35 mm low (#80136) was used for imaging T11 and
BLSL12 cells and IBIDI μ-Slide 8 well Grid-500 (#80826-
500G) was used for MDA-MB-231 time-lapse microscopy.
Brightfield images were acquired using a Zeiss Obser-
ver.A1 inverted microscope using AxioVision Micros-
copy Software.
Cytospin and co-immunofluorescence
Cells isolated by FACS were collected and about 30,000
cells were cytospun onto glass slides. Cells were fixed
with 4 % paraformaldehyde for 20 min at room
temperature followed by three washes in phosphate-
buffered saline (PBS) for 5 min each. Slides were stored
in 70 % ethanol at 4 °C overnight (or until use, no more
than 1 week).
For immunostaining, cells were rinsed twice with PBS
followed by one wash in PBS with Tween-20 (0.5 % Tri-
ton X-100 to ensure quenching of endogenous fluores-
cence), rinsed twice in PBS, and blocked for 1 hour
using 5 % goat serum +M.O.M. block (Mouse on Mouse
M.O.M. basic kit, Vector Labs, BMK-2202). Samples
were washed once in PBS followed by incubation for
5 min with 5 % goat serum +M.O.M. diluent. Primary
antibodies (1:200 dilution for each in 5 % goat serum +
M.O.M. diluent) were added to cells for 1 hour at room
temperature. Rabbit monoclonal antibody against vimen-
tin (Cell Signaling 5741) and mouse monoclonal anti-
body against pan-cytokeratin (Sigma C2562) were used
followed by three washes with PBS (no primary antibody
was added to the diluent for secondary only control).
Secondary antibodies were added in PBS for 1 hour at
room temperature (1:1000 dilution for both secondary
antibodies (Goat anti-Rabbit AlexaFluor 488 – Thermo
Fisher A11034, Goat anti-Mouse AlexaFluor 594 –
Thermo Fisher A11005) and washed four times with
PBS. A final wash containing 1 drop/mL DAPI in PBS
(NucBlue Fixed Cell Ready Probes, Thermo Fisher
R37606) was performed. Slides were mounted using
Aqua-Poly/Mount (Polysciences, Inc. 18606-20).
Flow cytometry
Briefly, all cells were harvested for flow cytometry using
the following protocol. Cells were trypsinized and neu-
tralized with growth medium containing 10 % FBS and
the medium was removed. Cells were resuspended in
HBSS+ (HBSS + 2 % FBS + HEPES buffer) and passed
through a 40-μm mesh filter.
For antibody staining of HMLER cells, anti-human
CD24-APC (eBioscience, clone eBioSN3, ref. 17-0247-42)
and anti-human/mouse CD44-eFluor 450 (eBioscience,
clone IM7, 48-0441-82) were diluted in HBSS+ at 1:50 di-
lution and used to resuspend cells. Cells were incubated
for 30 min at 4 °C, rinsed twice in HBSS+, resuspended in
HBSS+, and filtered through a 40-μm mesh filter.
Flow cytometry analysis was performed on BD LSR
Fortessa. Sorting was performed on BD AriaII. FlowJo
was used for the analysis.
Statistical analysis
All bar graphs indicate the mean value. All error bars
shown represent the standard deviation. Paired or un-
paired Student’s t tests were performed as indicated for
all statistical analyses.
Additional files
Additional file 1: Figure S1. miR-200 sensor construct and validation;
Z-cad sensor validation. A) Five miR-200 family binding sites were placed
downstream of d2GFP in the FUGW lentiviral expression vector. B)
Fluorescent microscopy of T11 cells containing the Z-cad dual sensor
after 4 days of doxycycline treatment. C) Flow cytometry analysis of
d2GFP-200 or control d2GFP expression and Ecad-RFP upon miR-200c/
141 induction after 4 days of 2 μg/mL doxycycline treatment in the
indicated cell lines (n = 3 biological replicates per group). D) Flow cytometry
analysis of BLSL12 breast cancer cells containing the indicated sensors. miR-
200c/141 was induced with 2 μg/mL doxycycline for 4 days. E) Fluorescent
confocal microscopy of BLSL12 cells containing Z-cad dual sensor after
4 days of doxycycline treatment. Scale bar = 20 μm. (TIF 4770 kb)
Additional file 2: Figure S2. Z-cad sensor loses GFP expression early
and gains RFP expression later upon miR-200c induction. All collected
time points for time-lapse microscopy (from Fig. 1c) of identical grids
within cell culture plate are shown for each treatment group. A) –DOX
control. B) 2 μg/mL DOX treatment to induce miR-200c. All time points
after DOX treatment are indicated. Scale bars = 50 μm. (TIF 9490 kb)
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Additional file 3: Figure S3. Decitabine treatment elicits RFP gain and
GFP loss using the Z-cad sensor. A) Flow cytometry analysis indicating
RFP+ cells (above horizontal line) and GFP low cells (left of vertical line).
GFP low/RFP+ are cells falling into top left quadrant. Quantitation is
shown in B). Unpaired Student’s t test was performed (n = 3 biological
replicates for vehicle and 500 nM; n = 2 for 100 nM). * p value < 0.05,
** p value < 0.01. (TIF 1358 kb)
Additional file 4: Figure S4. The Z-cad sensor enables isolation of
EMT-like MCF10A cells. A) FACS was performed on parental MCF10A cells
containing the Z-cad dual sensor to isolate GFPhiRFPlow/neg cells, which
comprise the EMT signature. Bulk–EMT group comprises all other cells.
B) RNA from each group collected in A) was isolated and qRT-PCR
performed for the indicated genes. Bulk–EMT cell values were set to 1.0 for
each gene and analyzed using a paired Student’s t test (n = 3 biological
replicates). (TIF 1316 kb)
Additional file 5: Figure S5. The Z-cad sensor can separate an EMT-like
cellular subpopulation during TGFβ1 treatment. A) RNA analysis of HMLER
cells isolated using EMT or Bulk–EMT fluorescence signatures during TGFβ1
treatment by qRT-PCR at indicated time points (n = 2 biological replicates
for 6 and 12 days; n = 3 biological replicates for 18 and 24 days). Bulk–EMT
cell values were set to 1.0 for each gene. Paired Student’s t test was
performed. * p value < 0.05, ** p value < 0.01. B) Cytospun HMLER cells
collected from EMT and Bulk–EMT fluorescence groups at 24 days of
TGFβ1 treatment. Immunofluorescence for pan-CK and vimentin was
performed. (TIF 2067 kb)
Additional file 6: Figure S6. Z-cad population gates and their CD24/
CD44 profiles. A) Flow cytometry analysis was used to gate HMLER cells
based on the indicated Z-cad expression profiles (in red boxes). Gated
cells from each population were subsequently analyzed for CD24 and
CD44 expression as shown in B). (TIF 1218 kb)
Additional file 7: Supporting Data. (XLSX 51 kb)
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